O Keefe Stevens Advisory Inc. Purchases 4,245 Shares of Pfizer Inc. $PFE

O Keefe Stevens Advisory Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% in the 2nd quarter, Holdings Channel.com reports. The fund owned 102,304 shares of the biopharmaceutical company’s stock after buying an additional 4,245 shares during the quarter. Pfizer comprises approximately 0.7% of O Keefe Stevens Advisory Inc.’s investment portfolio, making the stock its 26th largest position. O Keefe Stevens Advisory Inc.’s holdings in Pfizer were worth $2,480,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Northern Trust Corp boosted its holdings in Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares during the last quarter. Amundi boosted its holdings in Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Invesco Ltd. boosted its holdings in Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock worth $767,709,000 after purchasing an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock worth $715,581,000 after purchasing an additional 1,846,436 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PFE shares. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Bank of America raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.41.

Pfizer Trading Up 1.1%

Shares of Pfizer stock opened at $27.37 on Friday. The company’s fifty day simple moving average is $24.67 and its 200-day simple moving average is $24.14. The stock has a market capitalization of $155.59 billion, a PE ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.